Table 3 Relationship between SFXN1downregulation and clinicopathological factors in non-viral cases.
From: Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma
Variable | SFXN1high (n = 33) | SFXN1low (n = 11) | P-value |
|---|---|---|---|
Age (median) | 74 (48–85) | 73 (62–82) | 0.66 |
Sex | |||
 Male | 27 | 11 | 0.12 |
 Female | 6 | 0 |  |
Matteoni | |||
 0 | 18 | 6 | 0.87 |
 1, 2 | 8 | 2 |  |
 3, 4 | 7 | 3 |  |
Alcohol | 20 | 7 | 0.88 |
Diabetes | 15 | 5 | 1.00 |
Dyslipidemia | 9 | 5 | 0.26 |
Obesity | |||
 BMI > 25 | 15 | 8 | 0.12 |
 BMI ≤ 25 | 17 | 3 |  |
Plt | |||
 < 10 × 104/μL | 2 | 0 | 0.40 |
 ≥ 10 × 104/μL | 31 | 11 |  |
PT | |||
 < 80% | 6 | 2 | 1.00 |
 ≥ 80% | 27 | 9 |  |
Alb | |||
 < 3.5 g/dL | 4 | 1 | 0.78 |
 ≥ 3.5 g/dL | 29 | 10 |  |
AST | |||
 > 40 IU/L | 9 | 6 | 0.10 |
 ≤ 40 IU/L | 24 | 5 |  |
ALT | |||
 > 40 IU/L | 10 | 4 | 0.71 |
 ≤ 40 IU/L | 23 | 7 |  |
T-Bil | |||
 > 1.0 mg/dL | 4 | 2 | 0.61 |
 ≤ 1.0 mg/dL | 29 | 9 |  |
ICG | |||
 > 15% | 10 | 4 | 0.71 |
 ≤ 15% | 23 | 7 |  |
α-Fetoprotein (AFP) | |||
 > 200 ng/mL | 6 | 2 | 1.00 |
 ≤ 200 ng/mL | 27 | 9 |  |
PIVKA-II | |||
 > 100 mAU/mL | 14 | 6 | 0.48 |
 ≤ 100 mAU/mL | 19 | 5 |  |
Child–Pugh grade | |||
 A | 33 | 10 | 0.56 |
 B | 0 | 1 |  |
Tumor size | |||
 > 5 cm | 14 | 6 | 0.48 |
 ≤ 5 cm | 19 | 5 |  |
Tumor number | |||
 Solitary | 30 | 7 | 0.10 |
 Multiple | 3 | 4 |  |
Differentiation | |||
 Well | 12 | 3 | 0.58 |
 Poorly/moderately | 21 | 8 |  |
Portal vein invasion | |||
 0 | 25 | 6 | 0.18 |
 1, 2 | 8 | 5 |  |
 3, 4 | 0 | 0 |  |
Liver status | |||
 NL | 13 | 3 | 0.47 |
 CH/LC | 20 | 8 |  |
